Long-Term Risk of Anastomotic Ulceration After RYGB

Share this content:
Long-Term Risk of Anastomotic Ulceration After RYGB
Long-Term Risk of Anastomotic Ulceration After RYGB

FRIDAY, June 22, 2018 (HealthDay News) -- There is a significant long-term risk of anastomotic ulceration (AU) after Roux-en-Y gastric bypass (RYGB), which increases over time and with history of tobacco use, according to a research letter published online June 20 in JAMA Surgery.

Konstantinos Spaniolas, M.D., from Stony Brook University in New York, and colleagues describe the epidemiology of AU after RYGB using data for 35,075 adult patients who underwent laparoscopic or open RYGB for obesity. Patients were followed for a subsequent hospital-based diagnosis of AU.

The researchers found that the overall cumulative incidence of AU was 3.2, 4.5, 7.9, and 11.4 percent at one, two, five, and eight years after RYGB, respectively. Independent risk factors for AU development were identified and included history of tobacco use. The observed five-year incidence of AU varied from 5.2 to 15.9 percent for patients with zero to one and five or more risk factors, respectively. There was a significant correlation for history of tobacco use with AU development (adjusted hazard ratio, 1.56); at all points examined, cumulative incidence was significantly higher. In patients who used tobacco at the time of surgery, the estimated eight-year cumulative incidence of AU was 17.8 percent.

"The findings of this study underline that the incidence of AU after RYGB is more common than previously reported and that it progressively increases over time," the authors write. "The long-term effect of tobacco use on this complication is profound."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »